Epigenetic Therapeutics: Global Markets

Report Highlights

The global market for epigenetic therapeutics is estimated to increase from $6.8 billion in 2023 to reach $9.8 billion by 2028, at a compound annual growth rate (CAGR) of 7.7% from 2023 through 2028.

Report Includes

• 77 tables
• A comprehensive overview of the global markets for epigenetic therapeutics
• Analyses of the global market trends with historical market revenue data (sales figures) for 2020-2022, estimates for 2023, and projections of compound annual growth rates (CAGRs) through 2028
• Understanding of the upcoming market potential for epigenetic therapeutics with an emphasis on new products and technologies, and areas of focus to forecast this market into various segments and sub-segments
• Estimation of the actual market size and revenue forecast for the global epigenetic therapeutics market, and corresponding market share analysis product type and region
• In-depth information (facts and figures) concerning major market dynamics (DROs), technology advancements, new products and applications in epigenomics, and COVID-19 impact on the industry
• Coverage of the technological, economic, and business considerations of the market for epigenetic therapeutics, with analyses and growth forecasts through 2028
• A look at the recent breakthrough innovations, key technological issues, market regulations, and current status on the intellectual property rights on epigenetic therapeutics
• Review of patent trends and research publications for innovations in the genome-editing technologies
• Insight into the recent industry structure, government regulations and policies, development issues, and the vendor landscape
• Analysis of the competitive environment and market opportunities based on the company’s business strategies, product mapping, and operational integration
• Descriptive company profiles of the leading pharma corporations, including AstraZeneca, Bristol-Myers Squibb, GSK, Ipsen, Seagen, and Incyte

Report Scope

This report is a comprehensive study of the global market for epigenetic therapeutics. It describes the epigenetic therapeutics market, which is segmented by product type and region. Based on product type, the market is segmented into PRAP inhibitors, Kinase inhibitors, IDH inhibitors, HDAC inhibitors, DNMT inhibitors and KMT inhibitors. The market is segmented by region into North America, Latin America, Europe, Asia-Pacific, and the Rest of the World (RoW).

This report examines the factors driving growth in the epigenetic drugs market, and it reviews major players, established companies and new entrants.

This report, however, does not cover epigenetic diagnostic assays and instruments.

Analyst Credentials

BCC Research Team possesses expertise and experience in life and physical science domains. They specialize in offering valuable business insights, including industry analysis, competitor intelligence, strategic and financial analysis, and opportunity assessment. The team has in-depth knowledge of various sectors, including healthcare, biotechnology, pharmaceuticals, IT, automation, advanced materials, and energy. They are proficient in qualitative and quantitative market intelligence providing clients with actionable insights. With a vast understanding of the competitive landscape, the team can support clients in making data-driven decisions to help them achieve a competitive edge in their respective markets.